Swedish biotech Anocca has raised about 440 million Swedish kronor ($46 million) in new financing to accelerate development ...

The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay cancer recurrence in high-risk patients whose tumors are driven by KRAS ...